Form 4: Replimune Group Executive Christopher Sarchi Reports Acquisition of Shares and Stock Options

Christopher Sarchi, Chief Commercial Officer of Replimune Group, reports the acquisition of 45,000 shares of common stock and options to purchase 67,500 shares.

Summary

• On April 1, 2025, Christopher Sarchi, Chief Commercial Officer of Replimune Group, acquired 45,000 shares of common stock upon settlement of restricted stock units (RSUs).
• These RSUs vest over time, with 25% vesting on May 15, 2026, and the remainder in three approximately equal annual installments until May 15, 2029, contingent upon continued service.
• Sarchi also acquired an option to purchase 67,500 shares of common stock at an exercise price of $8.40.
• 25% of the shares underlying the stock option vest on April 1, 2026, with the remainder vesting in 36 approximately equal monthly installments thereafter.
• Following these transactions, Sarchi directly owns 132,045 shares of Replimune Group common stock and options to purchase 67,500 shares.

Sentiment

Score: 7

Explanation: The sentiment is neutral to positive. The granting of stock options and RSUs is a standard practice, and the executive's increased stake in the company can be seen as a positive sign.

Positives

• The acquisition of shares and stock options by a key executive signals confidence in the company's future prospects.

Industry Context

This type of equity compensation is common in the biotechnology industry to incentivize and retain key executives.

Stakeholder Impact

• The increased ownership stake of a key executive could positively influence shareholder confidence.

Key Dates

Keywords

Replimune Group, Christopher Sarchi, stock options, restricted stock units, Form 4, beneficial ownership, common stock, executive compensation